Thiopurine use by fathers at time of conception examined
- PDF / 123,276 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 97 Downloads / 170 Views
1
Thiopurine use by fathers at time of conception examined Researchers from Spain conclude that their study does not support "the practice of routinely recommending to male patients that they interrupt thiopurines when wanting to conceive". The study’s aim was to examine the outcomes of pregnancies fathered by men who were exposed to thiopurines for inflammatory bowel disease (IBD) treatment at the time of conception. A series of male patients attending IBD clinics in Madrid was analysed. In total there were 130 conceptions by 84 fathers; 46 conceptions (30 patients) were exposed to thiopurines, and 84 served as controls (54 patients; no thiopurine use for > 3 months prior to conception). Thiopurines were used for a median of 35 months before conception in the exposed group. Analysis showed there were no significant betweengroup differences in the rate of unsuccessful pregnancies – spontaneous abortions, ectopic pregnancies, anembryonic pregnancies or foetal deaths – (10.9% exposed group vs 13.1% control group: OR 0.79; 95% CI 0.22, 2.85), preterm births (4.3% vs 2.4%: 1.3; 0.22, 7.1), low birth weight (6.5% vs 6.0%: 1.06; 0.25, 4.54) or congenital malformations (2.2% vs 2.4%: 0.82; 0.08, 9.0). In terms of fertility, the proportion of conceptions that required > 1 year to be achieved was higher in the thiopurine exposed group than the control group, "but this was not statistically significant", say the researchers (15.2% vs 8.3%: 1.92; 0.54, 6.88). Teruel C, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. American Journal of Gastroenterology : 10 Aug 803036574 2010. Available from: URL: http://dx.doi.org/10.1038/ajg.2010.138
0114-9954/10/1318-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 11 Sep 2010 No. 1318
Data Loading...
